NASDAQ:DSGN

Design Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy DSGN

*Your capital is at risk

$12.18

-0.440 (-3.49%)

At Close: Jul 31, 2026

Design Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -15.46. In total, the insiders bought 16.33M and sold 2.76M DSGN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-15.46
● Buy	16.33M shares
● Sell	2.76M shares
92% Buy Activity Moderate Positive Correlation
Buy Signal Medium Confidence Jun 09, 2026 Analysis Breakdown: Weakened by a contradictory negative Insider Power Score. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (92% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 10, 2025 Buy	Stock Option (right to buy) A-Award	George Simeon	Director	19 000 Value: $76.2K
Jun 10, 2025 Buy	Stock Option (right to buy) A-Award	Prasad Deepa Director	Director	19 000 Value: $76.2K
Jun 10, 2025 Buy	Stock Option (right to buy) A-Award	William Arsani Director	Director	19 000 Value: $76.2K
Jun 10, 2025 Buy	Stock Option (right to buy) A-Award	Berger Heather A. Director	Director	19 000 Value: $76.2K
Jun 10, 2025 Buy	Stock Option (right to buy) A-Award	Schmid John P. Director	Director	19 000 Value: $76.2K
Jun 10, 2025 Buy	Stock Option (right to buy) A-Award	Lappe Rodney W Director	Director	19 000 Value: $76.2K
Jun 10, 2025 Buy	Stock Option (right to buy) A-Award	Lappe Rodney W Director	Director	19 000 Value: $76.2K
Jun 10, 2025 Buy	Stock Option (right to buy) A-Award	Schmid John P. Director	Director	19 000 Value: $76.2K
Jun 10, 2025 Buy	Stock Option (right to buy) A-Award	Berger Heather A. Director	Director	19 000 Value: $76.2K
Jun 10, 2025 Buy	Stock Option (right to buy) A-Award	William Arsani Director	Director	19 000 Value: $76.2K
Jun 10, 2025 Buy	Stock Option (right to buy) A-Award	Prasad Deepa Director	Director	19 000 Value: $76.2K
Jun 10, 2025 Buy	Stock Option (right to buy) A-Award	George Simeon	Director	19 000 Value: $76.2K
May 01, 2025 Buy	Stock Option (right to buy) A-Award	Storgard Chris Chief Medical Officer	Officer	400 000 Value: $1.88M
May 01, 2025 Buy	Stock Option (right to buy) A-Award	Storgard Chris Chief Medical Officer	Officer	400 000 Value: $1.88M
Apr 16, 2025 Buy	Common Stock J-Other	Storgard Chris Insider	Other	0 Value: $0
Apr 16, 2025 Buy	Common Stock J-Other	Storgard Chris Insider	Other	0 Value: $0
Jan 02, 2025 Buy	Stock option (right to buy) A-Award	Shah Pratik President, CEO And Chairperson	CEO / President	600 000 Value: $3.70M
Jan 02, 2025 Buy	Stock option (right to buy) A-Award	Jeffries Sean Chief Operating Officer	C-Suite Officer	260 000 Value: $1.60M
Jan 02, 2025 Buy	Stock option (right to buy) A-Award	Lappe Rodney W Director	Director	25 993 Value: $160.4K
Jan 02, 2025 Buy	Stock option (right to buy) A-Award	Burgess Julie Chief Accounting Officer	Officer	135 000 Value: $833.0K
Jan 02, 2025 Buy	Stock option (right to buy) A-Award	Jeffries Sean Chief Operating Officer	C-Suite Officer	260 000 Value: $1.60M
Jan 02, 2025 Buy	Stock option (right to buy) A-Award	Shah Pratik President, CEO And Chairperson	CEO / President	600 000 Value: $3.70M
Jan 02, 2025 Buy	Stock option (right to buy) A-Award	Burgess Julie Chief Accounting Officer	Officer	135 000 Value: $833.0K
Jan 02, 2025 Buy	Stock option (right to buy) A-Award	Lappe Rodney W Director	Director	25 993 Value: $160.4K
Dec 18, 2024 Sell	Common Stock S-Sale	Prasad Deepa Director	Director	3 806 Value: $23.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT DESIGN THERAPEUTICS, INC.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysf...

Read Full Profile Here